Bollinger Ingel-Hengham-Hehua ® can be ® approved by the China Drug Administration

recently Bollinger Ingham announced that the ® of siphonsofler ® (Pyro Brominamon/Odatro Inhalation Spray) has been officially approved by the ChinaDrug(Supervisory Authority for long-term maintenance treatment for patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema)on the silihua ® (Ammon Perbromine)Silihua ® (Ito Brominam) is a classicdrugfor the treatment of slow-blocking pulmonary stabilization (on this basis, Bollinger Ingerham has developed a new high-efficiency injection of long-lasting beta2 receptor agonist Odatro, the two strong combination, synergy (5 minutes after the use of the drug, improve lung function, the effect can last 24 hours
) Sihehua ® energy pire ® is also the only current field of slow-resisting pulmonary treatment containing ammonium pyrobutte bromine, and only by the original soft mist inhalation device can be delivered by the pylon ® of the double bronchial dilatator (double expansion agent)In China, the recommended dose for adults approved is 5 ?g/Odatro 5 sg, once dailyrelated research
TOviTO PHASE III clinical research program fully confirms the effectiveness and safety of the ® of Sihehua can be pired ® the treatment of copl pulmonary resistance
The TOviTO program, which included eight series of clinical studies and included more than 15,000 patients with CPR worldwide, showed that sihua ®® improving the main clinical indicators of stator-impedance (including pulmonary function, breathing difficulties, acute aggravation and quality of life) compared to the pyrotrophic ammonium spray, and that several studies consistently demonstrated that the efficacy was consistent with a double bronchial dilatator that exceeded the pangonomine, and that safety was comparable to monotherapyToNADO'sanalysis(including 549 Chinese patients) and a recently published VESUTO study further confirm that the efficacy of the ®-based pylon stort ® treatment of patients with chronic obstructive pulmonary in East Asia is consistent with global dataIn addition, a number of authoritative studies have shown that the double bronchial dilatants represented by the ® of siphono-® are superior to glucocorticoids/long-acting beta-2 receptor agonists (ICS/LABA) in improving lung function, alleviating breathing difficulties, and preventing acute exacerbation